Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Quality Assurance Units<br />
Chapter 3 (Articles 9 <strong>and</strong> 10)<br />
Structures, facilities <strong>and</strong> equipment of<br />
test<strong>in</strong>g facilities<br />
Chapter 4 (Articles 11 <strong>and</strong> 12)<br />
St<strong>and</strong>ard operat<strong>in</strong>g procedures <strong>in</strong> test<strong>in</strong>g<br />
facilities (prepared by management) <strong>and</strong><br />
animal caretakers<br />
Chapter 5 (Articles 13 <strong>and</strong> 14)<br />
H<strong>and</strong>l<strong>in</strong>g of <strong>in</strong>vestigational products <strong>and</strong><br />
comparators<br />
Chapter 6 (Articles 15 <strong>and</strong> 16)<br />
Study protocols (prepared by study<br />
director) <strong>and</strong> proper conduct of studies.<br />
Chapter 7 (Articles 17 <strong>and</strong> 18)<br />
F<strong>in</strong>al reports (prepared by study director)<br />
<strong>and</strong> retention of study data<br />
Chapter 8 (Article 19)<br />
Requirements for conduct<strong>in</strong>g studies at<br />
more than two test<strong>in</strong>g facilities<br />
Verification of the GLP ord<strong>in</strong>ance<br />
compliance of study facilities perform<strong>in</strong>g<br />
noncl<strong>in</strong>ical studies <strong>in</strong> compliance with the<br />
GLP ord<strong>in</strong>ance (GLP-compliant studies)<br />
at the time of approval reviews is<br />
performed as a rule based on the results<br />
of paper <strong>and</strong> on-site reviews by the<br />
PMDA at the request of the MHLW <strong>and</strong><br />
the MHLW decides on whether or not to<br />
accept the data concerned as approval<br />
<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />
review data.<br />
GLP compliance reviews conducted<br />
by the PMDA are performed on the basis<br />
of the “System of Guidel<strong>in</strong>es for Reviews<br />
Based on the <strong>Pharmaceutical</strong> GLP <strong>and</strong><br />
Medical Device GLP” (Notification No. 23<br />
of the PMDA date April 1, 2004; partially<br />
revised Notifications No. 530 of the PMDA<br />
dated June 29, 2004, No. 529 dated<br />
March 30, 2007, No. 0620058 dated June<br />
20, 2008 <strong>and</strong> No. 0815008 dated August<br />
15, 2008). GLP compliance conditions<br />
are evaluated <strong>in</strong> the follow<strong>in</strong>g three<br />
categories by the GLP Evaluation<br />
Committee established by the PMDA<br />
based on the results of the GLP<br />
compliance review.<br />
Class A: Compliance with GLP.<br />
Class B: Some improvements possible<br />
but the effects of non-compliance<br />
on data reliability are considered<br />
tolerable; compliance with GLP if<br />
improvements are made.<br />
Class C: Noncompliance with GLP.<br />
When evaluated as Class A or B <strong>in</strong> the<br />
GLP compliance reviews, the results of<br />
the tests performed <strong>in</strong> the facility will be<br />
accepted, <strong>in</strong> pr<strong>in</strong>ciple, for use as review<br />
data for a period of 3 years or 2 years,<br />
respectively, from the day of notification of<br />
2011-3 - 80 -